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malignant gliomas, primary 
brain tumours 
Malignant glial tumours are the most common primary brain tumours and the most 
aggressive and difficult to treat. Gliomas present heterogeneity histologically, geneti-
cally and in their outcome. Despite decades of intense research in this field, there 
has been little improvement in mortality rates because of the tumours’ inter- and 
intra-tumoural heterogeneity and predisposition of the cancerous cells to infiltrate 
normal parenchyma of the brain. Gliomas have been traditionally categorized based 
on their histopathological features, but it has become obvious that this classification 
alone has its limitations. Recently, expression studies have indicated that by using 
molecular signatures, malignant glial tumours can be categorized into subclasses that 
can more effectively predict patient outcome. The use of molecular markers that carry 
both prognostic and diagnostic information on tumours with histologically reminis-
cent appearance adds another level of complexity, reduces inter-observer variability, 
and allows better characterization of novel tumour variants and entities. In modern 
neuro-oncology, molecular markers have become essential in tumour evaluation, and 
molecular marker status of a glioma now guides clinical decision-making. This review 
will discuss general aspects of malignant gliomas, their grading and staging, genetic 
information and relevant molecular markers, as well as future perspectives in the 
treatment and classification of these gliomas. 
iNTroDuCTioN
Malignant gliomas are the most common 
primary mal ignant brain tumours. In 
contrast to primary brain tumours, the 
term secondary brain tumour refers to 
a metastatic tumour, i.e. cancer that has 
spread to the brain from its point of origin. 
Current treatment strategies for primary 
malignant brain tumours and in particular 
malignant gliomas include maximally safe 
surgical resection of the tumour followed 
by adjuvant therapies like radiation- and 
chemotherapy. Because these tumours 
present a highly malignant character, they 
are very difficult to eliminate completely, 
despite the above aggressive therapeutic 
interventions (1).
Difficulties in treatment of malignant 
gliomas stem from their diffusely infiltra-
tive growth pattern, that follows no clear 
boundaries, and their indiscriminate proli-
feration into surrounding tissue, factors 
that both notably limit the extent of safe 
surgical resection and make a complete 
resection of the tumour very challenging. 
Additionally, these tumours are often also 
resistant to adjuvant therapies like chemo-
therapy. After diagnosis, the overall survival 
of a patient with malignant glioma can be 
as low as 12-14 months despite contemporary 
therapeutic interventions. Currently used 
treatments are for the most part merely 
delaying the recurrence and prolonging of 
patient survival (1, 2).
Traditionally, gliomas have been catego-
rized on their histopathological features (3). 
World Health Organization (WHO) released 
an updated and anticipated edition of the 
Classification of Tumours of the Central 
Nervous System in 2016. In contrast to the 
previous 2007 edition, molecular parameters 
are used for the first time, in addition to 
histology, to define tumour entities, thus 
formulating a concept of how diagnoses of 
tumours of the central nervous system (CNS) 
should be structured in the molecular era (4). 
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able to penetrate the blood-brain barrier and 
affect the brain tissue. These include agents 
like temozolomide (TMZ) and nitrosurease 
that are highly lipid soluble and have low 
molecular weight (9). An additional factor 
that complicats the use of adjuvant thera-
pies for treatment of malignant gliomas is 
the intrinsic heterogeneity of the tumour 
microenvironment and its cell populations. 
Regarding the overall result, adjuvant treat-
ments have often been merely able to delay 
tumour recurrence and prolong patient 
survival (1, 2). 
grADiNg AND sTAgiNg
A numerical grade of II, III or IV is used 
to describe the extent of the tumour’s 
morphological features (illustrative pictures 
1, 2 and 3), for example, its microvascular 
proliferation found at pathological evalua-
tion (10, 11). The current histopathological 
WHO classification also includes grade I 
tumours, for example, pilocytic astrocy-
toma, which, due to their potential for 
malignant transformation are also conside-
red low-grade gliomas. The purpose of the 
grading is to identify the aggressiveness 
or the malignancy of the tumour and to 
ref lect its predicted biological behaviour. 
A higher grade indicates a more malignant 
tumour and, as a rule, patients have a better 
prognosis with a lower grade tumour (11). 
It should be noted that high grade gliomas 
(grades III, IV) can develop from a low grade 
tumour that was previously present. Tumour 
Picture 1. Grade II oligodendroglioma, 
IDH-mutant.
WhAT Are mAligNANT gliomA s?
Glioma is a general term used to describe 
any tumour in the CNS that emerges 
from glial cells. Glial cells, also referred 
to as neuroglia or glia, are non-neuronal 
supportive cells of the nervous system. 
Glia keep neurons in place and assist their 
functioning. Glial cells in the CNS include 
astrocytes, ependymal cel ls, ol igoden-
drocytes and microglia. Consequently, 
gliomas are classif ied according to the 
respective cell type involved in the tumour, 
i.e. into oligodendroglioma, astrocytoma, 
medulloblastoma, ependymoma and mixed 
glioma (2). 
Patients with malignant gliomas are 
usually highly symptomatic. These symp-
toms vary by tumour type but also by rate 
of growth and size and location of tumour 
effects. Some of the most common symp-
toms include headaches, seizures, nausea, 
vomiting, neurocognitive dysfunctions, 
motor deficits, and vision problems like 
blurred v ision, double v ision or loss of 
peripheral vision (5). Glioma diagnosis can 
be made by means of magnetic resonance 
imaging (MRI ), computed tomography 
scan (CT scan), biopsy or angiogram, with 
contrast enhanced MRI being the most 
common method used. Because gliomas are 
characterized by invasiveness, diffused cells 
invariably exist beyond the imaged tumour. 
Visualization of all cells in a given tumour 
by common imaging techniques is therefore 
nearly impossible (6). Prognosis and treat-
ment modalities depend, for example, on 
the localization of the tumour, its degree 
of malignancy, proliferation activity, as well 
as the genetic profile and patient age (7).
Invasive gliomas have high recurrence 
rate and low cure rate despite the combining 
of surgery and adjuvant therapies, currently 
used for their treatment (1). One of the prob-
lems concerning treatment is that chemo- 
and radiation therapies target tumour cells 
in their growth phase, but fail to affect 
quiescent glioma stem cells, i.e. subsets of 
tumour cells driving tumorigenesis by their 
potential for self-renewal (2, 8). The blood-
brain barrier in the brain is an additional 
complicating factor to effective therapy 
because it inhibits adequate therapeutic 
concentration of most chemotherapeutic 
agents in tumour mass and peritumoural 
area, leading to suboptimal therapeutic 
response (3, 9). Only a few known agents are 
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Picture 3. Grade IV glioblastoma multiforme, 
1p19q co-deleted.
Source of MRI pictures: Tartu University Hospital
progression from a lower to a higher grade 
cannot be predicted, but approximately 
two-thirds of all low-grade gliomas advance 
to higher grade tumours. Staging indicates 
whether the tumour has spread or not. CNS 
tumour staging is typically performed based 
on MRI images, CT scans or by an examina-
tion of cerebrospinal f luid (12).
Grade IV glioblastomas typically have 
histo-morphological features that include 
intra-tumoural necrosis, increased proli-
feration, i.e. increased mitotic rate, nuclear 
atypia/pleomorphism, and microvascular 
proliferation (13). 
    
geNeTiC iNFormATioN AND 
moleCul Ar mArkers oF 
gliomA s
Significant progress has been made in the 
last decade to illuminate the underlying 
genetic causes of gliomas (14). The resulting 
molecular and genetic markers have been 
shown to be important in supplementing 
histological analyses for a more precise 
def init ion of distinct disease entit ies. 
Molecular classifications of gliomas have 
become seminal also in terms of patient 
survival and prognosis, since classification 
of gliomas according to their molecular 
features is presumed to better reflect their 
clinical outcome and behaviour (1). Delivery 
of highest quality treatment requires there-
fore an understanding of these molecular 
characteristics of malignant gliomas (2).
Important molecular markers for malig-
nant gliomas include 1p19q co-deletion, 
O6-methylguanine- DNA methyltransferase 
(MGMT) promoter methylation, isocitrate 
dehydrogenase (IDH) encoding gene muta-
tion, Ki-67, and epidermal growth factor 
receptor variant III (EGFRvIII) amplifica-
tion (2). The above markers are described 
in more detail below.
It should be noted that currently no 
single molecular marker expresses the 
condition of all gliomas. Instead, a combina-
tion of molecular markers is used to evaluate 
the prognosis and response to treatment 
in glioma patients. For example, 1p19q 
deletion often exhibits also IDH mutations. 
A combination of MGMT promoter methyla-
tion, IDH mutation and 1p19q co-deletion 
is thought to greatly increase the survival 
rates of patients (2).
1p19q co-deletion 
The so called 1p19q co-deletion occurs 
at the short arm of chromosome 1 (1p) 
and at the long arm of chromosome 19 
(19q ). Gl iomas that have a prominent 
oligodendroglial component like grade II 
oligodendrogliomas,often involve allelic loss 
in 1p. In mixed gliomas and oligodendro-
glial tumours, the incidence of allelic loss 
in 19q is notably high (2).
In patients with 1p19q co-deletion, the 
rate of response to chemotherapy with 
temozolomide (TMZ) has been shown to 
be better compared to the patients without 
it, and the growth rate of the tumour 
measured by its diameter was found to be 
Picture 2. Grade III astrocytoma anaplasticum.
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lower compared with other patients. 1p19q 
co-deletion may also delay the development 
of TMZ resistance. Additionally, 1p19q 
co-deletion serves as an important indicator 
of chemo-sensitivity and prognosis of low-
grade gliomas. For example, among grade II 
oligodendroglioma patients, 5-year survival 
rates with 1p19q co-deletion were found to 
be considerably higher than among patients 





(MGMT) is an omnipresent DNA repair 
enzyme that plays a crucial role in cellular 
DNA damage resistance. DNA damage is 
induced by alkylating agents, for example 
TMZ, that remove the alkyl group from the 
O6-atom of guanine. Because MGMT protein 
acts as methyl acceptor and methyltrans-
ferase for inactivation of MGMT during 
methylation, the process does not require 
co-factors. It has been proven in clinical 
trials that methylation of MGMT promoter is 
a positive prognostic marker that results in 
the tumours being more sensitive to radia-
tion therapy (15). According to evidence, 
MGMT methylation is a positive predictive 
marker for the responsiveness to alkylating 
agents of newly diagnosed gl iomas. In 
gl ioma patients with MGMT promoter 
methylation, TMZ chemotherapeutic sensi-
tivity has been found to be greater than in 
patients without the methylation, and is 
consequently, a sign of better prognosis (2). 
Isocitrate dehydrogenase encoding 
gene mutation
Isocitrate dehydrogenase (IDH) is one of 
the major players in human metabolism and 
has two variants, IDH1 and IDH2. Isocitrate 
dehydrogenase encodes IDH that catalyses 
the oxidative decarboxylation process that 
yields α-ketoglutarate and carbon dioxide. 
NADP+ is used as a co-factor for IDH1 and 
IDH2 for catalysing the reaction. More 
than 70% of malignant gliomas exhibit IDH 
mutations with the IDH1 variant being the 
most frequent mutation (in over 95% of 
cases). The mutation occurs at R132H, i.e. 
in the single amino acid residue of IHD1 
active site, and it leads to the inability 
of the enzyme to catalyse the conversion 
of isocitrate to α-ketoglutarate. Instead, 
IDH1 mutant catalyses α-ketoglutarate to 
2-hydroxy glutaric acid that is associated 
with malignant transformations. IDH1 
mutation is an early molecular marker in the 
prognosis and diagnosis of glioma patients 
because it is the earliest and most frequent 
genetic change in a glioma (2). 
Ki-67
Ki-67 is a cell proliferation nuclear antigen 
and a marker of cell division. Malignancy 
of tumour cells and their proliferation may 
be reflected objectively by Ki-67 levels (16). 
Ki-67 is also an important marker for differ-
entiation of malignant and benign tumours. 
This is so because the overexpression of 
Ki-67 results in increased invasiveness 
and proliferation, which in turn leads to 
a higher grade of malignancy, recurrence 
of the tumour and dismal prognosis for 
glioma patients (17, 18). 
Epidermal growth factor receptor 
variant III amplification 
Epidermal growth factor belongs to the 
receptor tyrosine kinase (RTK) family, 
a membrane receptor superfamily that 
exhibits protein tyrosine kinase activity. 
A particular mutation of epidermal growth 
factor receptor (EGFR), named EGFR variant 
III (EGFRvIII), is often found in conjunction 
with glioblastomas. In 25–30% of patients 
with malignant gliomas, active mutant 
EGFRvIII is known to be present with EGFR 
overexpression or amplification (19, 20). By 
activating other RTKs, EGFRvIII plays a role 
in tumorigenesis (2). Greenall et al (21) have 
shown that in U87MG type glioma cells, 
EGFRvIII activity is directly proportional 
to MET transactivation. In a mouse model, 
targeting of both transactivated RTKs and 
EGFRvIII simultaneously led to notably better 
survival of the test subject. This indicates that 
by blocking both EGFRvIII and transactivated 
RTK may be an effective treatment option 
for EGFRvIII–positive glioma conditions (2). 
FuTure perspeCTiVes
Understanding of the genetic basis of tumori- 
genesis has increased markedly thanks 
to studies conducted over the past two 
decades. This has challenged traditional 
tumour classif ications that have been 
devised on the basis of histogenetic descrip-
tions of microscopic similarities and that 
have relied on ultrastructural characteriza-
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tions, immunohistochemical expressions of 
lineage-associated proteins, and descrip-
tions of hematoxylin & eosin –stained 
sections of light-miscroscopic analyses. In 
the WHO Classification of Tumours of the 
Central Nervous System 2007, the use of 
genetic alterations already provided predic-
tive or prognostic data within the diagnostic 
categories established on a histological 
basis. In 2016, WHO released an updated 
edition of the Classification of Tumours of 
the Central Nervous System that finally used 
molecular parameters for the first time in 
addition to histology in defining tumour 
entities, thus formulating a concept speci-
fying how CNS tumour diagnoses should be 
structured in the future (4).
Use of integrated geno- and phenotypic 
parameters for the classification of CNS 
tumours has the potential for providing 
a new level of objectiv ity, compared to 
the diagnostic processes used in the past. 
This new level of objectivity stems from 
more narrowly defined and biologically 
homogenous diagnostic entities, and will 
hopefully lead to improved patient manage-
ment, greater accuracy in diagnostics, and 
more accurate determination of treatment 
response and prognosis. It is noteworthy that 
the diagnostic use of both molecular genetic 
and histological features can potentially 
lead to contradictory results in which case 
(according to the new WHO classification) 
the genotype surpasses the histological 
phenotype. Consequently, it can be asked 
whether in the future, classification could 
proceed without the use of histology, i.e. 
based solely on the genotype. At this point 
an exclusively genotypic classification is not 
possible because it is still required to make 
a diagnosis of diffuse gliomas to understand 
the clinical and nosological meaning of 
certain genetic changes. Also, WHO grades 
are still determined on the basis of histolog-
ical criteria. Additionally, individual tumours 
exist that do not fit into a more narrowly 
defined geno- and phenotype criteria, which 
emphasizes the need to retain the phenotype 
as a basis for classification (4). 
The new WHO framework is a “layered 






Layer 1 represents the final “integrated 
diagnosis”, but information from all lower 
layers must first be gained. As mentioned 
above, as a general rule, molecular informa-
tion surpasses histology. The principle of 
NOS i.e. “not otherwise specified” was also 
presented in the WHO 2016 classification, 
meant to be used for example in situations 
where the sample does not allow testing 
(22, 23).
Increasing the understanding of malig-
nant glioma biology and behaviour to the 
level where targeted curative therapy could 
be developed is crucial in the future. A direct 
fallout is that genomic technology needs to 
become more available in clinics in order 
administer more personalized precision 
therapies like tailored treatments based on 
molecular information on various gliomas, 
tissue sequencing, and analysis of data for 
individual therapeutic recommendations. 
Undoubtedly, this requires a multidiscipli-
nary approach in tackling the complexity 
presented by malignant tumours. Neverthe-
less, a significant amount of information 
already exists on, for example, gliomagenesis 
–related genetic pathways and biological and 
clinical behaviour of malignant tumours. 
Integrating this type of multidisciplinary 
information is essential in gaining a compre-
hensive view on the genetic and cellular 
mechanisms underlying tumour biology, 
and in developing and providing effective 
targeted therapies (24, 25). 
The ability to routinely perform mole-
cular characterizations of gliomas, advances 
in imaging and advanced targeting therapies 
will improve the management of gliomas in 
the future. A major issue in the successful 
treatment of gl iomas l ies in gaining a 
broader understanding of the molecularly 
defined subsets that could differentiate 
various gl iomas into dif ferent disease 
entities. This could have the potential to 
develop more effective targeted therapies 
addressing driver mutations. Advances in 
mechanisms of delivery of drugs to tumours 
will also improve patient outcomes (24).
summAry 
Today when precision medicine is becoming 
a norm in treatment of gliomas, a specific 
diagnosis that integrates histological infor-
mation, tumour grade and molecular data is 
required. Owing to advances in molecular 
biotechnologies in recent years, molecular 
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characterization of gliomas has improved 
significantly, leading to attempts at person-
alized medicine and molecularly targeted 
therapies. These are thought to be the future 
breakthroughs also in gl ioma therapy. 
Molecular classif ication of gliomas will 
likely be performed routinely in the future 
to guide different therapeutic options and 
to develop novel drugs that will likely also 
improve therapeutic outcomes. All things 
considered, immense hope exists that the 
latest WHO Classification of Tumours of the 
Central Nervous System 2016 will facilitate 
the epidemiological, experimental and 
clinical studies leading to improvements 
in the lives of brain tumour patients.
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